Product · #7 of 27 · multi-symptom

Nature's Bounty Optimal Solutions Advanced Menopause Relief

Tablet from Nature's Bounty, made by Nestlé Health Science. Daily serving: 1 tablet with a meal.

Last updated · Price and ratings checked Nov 19, 2026

In short: Nature's Bounty Optimal Solutions Advanced Menopause Relief scores 56.7/100 in our ranking (#7 of 27). It costs $0.67 a day at the regular price. Evidence: ERr 731 4 mg + affron saffron (mood); best ingredient grade C (ERr 731 rhapontic rhubarb). No NSF registry listing was confirmed.

Pros

  • Low cost: $0.67 a day at the label dose.
  • Evidence: ERr 731 4 mg + affron saffron (mood).

Cons

  • No NSF registry listing confirmed.

Flags

None found

Score breakdown

Evidence
29/40
NSF-verified testing
4/20
Value ($/day)
15.5/20
Ingredients
4/10
Amazon rating
4.2/10

How we score

Full label: what's in it

Supplement Facts actives per daily serving (1 tablet with a meal). Source: label or official page, checked Nov 19, 2026.
Ingredient (as labeled)Per dayEvidence page
Rhapontic (Siberian) rhubarb extract ERr 731 (2.2 mg rhaponticin + 1 mg desoxyrhaponticin)4 mgERr 731 rhapontic rhubarb C
Saffron extract affron (Crocus sativus stigma)28 mgSaffron (affron) C

Same ERr 731 active and dose as Estroven Complete, plus affron saffron. U.S. News lists this product as containing genistein; the official label says otherwise.

Evidence

Our evidence score: 29/40, because: ERr 731 4 mg + affron saffron (mood).

Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.

Ingredient evidence

  • ERr 731 rhapontic rhubarb C (4 mg here)
    ERr 731 is a rhapontic rhubarb root extract (the active in Estroven Complete) studied in perimenopausal women for occasional hot flashes and related symptoms*. The placebo-controlled trials come from one research group. The Menopause Society 2023: Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study.
  • Saffron (affron) C (28 mg here)
    Saffron extract has been studied for occasional low mood and feelings of anxiousness in perimenopause*. In the largest menopause trial it did not reduce hot flashes. The Menopause Society 2023: Not assessed.

Studies

Studies on its ingredients (6)
  • Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial.

    Heger M, Ventskovskiy BM, Borzenko I et al. · Menopause 2006 · ERr 731 rhapontic rhubarb

    109 perimenopausal women took the rhubarb-root extract ERr 731 (sold as Estrovera/Estroven Complete) or placebo for 12 weeks. Symptoms including hot flashes improved strongly. However, most women on placebo dropped out, which makes the comparison less reliable.

    Who
    109 perimenopausal women
    Dose
    ERr 731 one tablet/day (4 mg)
    Duration
    12 weeks
    Result
    MRS total and each symptom improved vs placebo (P<.0001); fewer and milder hot flushes from week 4; no endometrial changes. NAMS notes only 7/55 placebo completers.
    Funding
    Authors from Health Research Services Ltd; manufacturer (Dr. Loges) funding not stated in abstract. Industry-linked

    PubMed · Full text (DOI)

  • Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.

    Kaszkin-Bettag M, Ventskovskiy BM, Solskyy S et al. · Altern Ther Health Med 2009 · ERr 731 rhapontic rhubarb

    A second 12-week trial by the same research group (112 women) again found large improvements with ERr 731 versus placebo. Independent replication is still lacking.

    Who
    112 perimenopausal women
    Dose
    ERr 731 one tablet/day
    Duration
    12 weeks
    Result
    MRS total 27.0→12.4 vs 27.0→24.0 placebo (P<.0001); hot flushes reduced.
    Funding
    Same research group as the original trial; funding not stated in abstract. Industry-linked

    PubMed

  • Efficacy evaluation of standardized Rheum rhaponticum root extract (ERr 731 (®)) on symptoms of menopause: A systematic review and meta-analysis study.

    Dubey VP, Sureja VP, Kheni DB · J Biomed Res 2024 · ERr 731 rhapontic rhubarb

    A pooled analysis of 4 ERr 731 studies found large symptom reductions, but the analysis was written by staff of a company that sells the extract.

    Who
    4 studies, 390 women
    Dose
    ERr 731
    Duration
    12 weeks
    Result
    Pooled MRS reduction -15.1 points vs control (P<.001).
    Funding
    Lead authors from Sundyota Numandis (Indian distributor) – industry-affiliated. Industry-linked

    PubMed · Full text (DOI)

  • Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.

    Heger PW, Hotz D, Kalder M et al. · Breast Cancer Res Treat 2025 · ERr 731 rhapontic rhubarb

    In German medical records, women prescribed ERr 731 were not more likely to be diagnosed with breast cancer than women who were not. This is observational, partly industry-linked data.

    Who
    5,686 users vs 17,058 non-users (German records)
    Dose
    ERr 731 prescriptions
    Duration
    observational
    Result
    No increase in breast-cancer diagnosis (OR 1.01, 95% CI 0.81–1.26).
    Funding
    Two authors employed by Health Research Services GmbH. Industry-linked

    PubMed · Full text (DOI)

  • The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study.

    Lopresti AL, Smith SJ · J Menopausal Med 2021 · Saffron (affron)

    86 Australian women in perimenopause took saffron extract or placebo for 12 weeks. Mood and anxiety improved more with saffron, but hot flashes did not. The saffron supplier funded the study.

    Who
    86 perimenopausal women
    Dose
    saffron extract (affron) 14 mg twice daily
    Duration
    12 weeks
    Result
    Improved psychological symptoms (anxiety -33%, depression -32%) vs placebo; no effect on hot flashes.
    Funding
    Funded by Pharmactive Biotech (affron maker). Industry-linked

    PubMed · Full text (DOI)

  • Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial.

    Kashani L, Esalatmanesh S, Eftekhari F et al. · Arch Gynecol Obstet 2018 · Saffron (affron)

    60 Iranian women with depression and hot flashes took saffron (30 mg a day) or placebo for 6 weeks; both mood and hot-flash bother improved more with saffron. Small and short.

    Who
    60 postmenopausal women with depression and hot flashes
    Dose
    saffron 15 mg twice daily
    Duration
    6 weeks
    Result
    Hot-flash interference and depression scores improved vs placebo.
    Funding
    Academic (Iran). Independent / academic

    PubMed · Full text (DOI)

The Menopause Society's 2023 statement is in the study library.

Price

Regular one-time price$19.99 (30 units, 30 days at label dose)
Cost per day$0.67
SubscriptionAmazon S&S $15.65
Price notesNo DTC; Amazon list $19.99 (B0DX84QTPP, now $16.47); Walmart $19.97; drugstores much higher (CVS $41.79, Walgreens $34.99–41.99)
In stock when checkedYes
CheckedNov 19, 2026

Ratings

Amazon: ★ 4.3 from 391 ratings on Amazon (checked Nov 19, 2026)

Star ratings reflect buyer satisfaction, not clinical effect.

Certifications and claims

Verified in a public registry

  • No registry listing found.

Claims made by the brand

  • “vegan” Brand claim
  • “non-GMO” Brand claim
  • “no added hormones” Brand claim
  • “no soy/gluten/dairy” Brand claim

Registry check: NSF/ANSI 173 ('Nature's Bounty'): not found

Who's behind it

BrandNature's Bounty
Owner / companyNestlé Health Science (naturesbounty.com footer).
FoundersNot stated on the pages we read.
Where it's madeMade in the USA (iHerb listing).
Medical advisors namedNone named on the pages we read.
Sourcenaturesbounty.com

Flags & safety

Legal, regulatory and quality flags

No lawsuits, regulator actions or watchdog complaints found in our search for this product or brand.

Ingredient safety notes

  • ERr 731 rhapontic rhubarb: Post-marketing (Germany, ~140M daily doses): mainly hypersensitivity and GI complaints. Observational German data: no increase in breast-cancer diagnosis (OR 1.01, industry-linked). Endometrium unchanged in trials. Contains ER-β–active compounds.
  • Saffron (affron): Well tolerated at 28–30 mg/day.

Sources

Talk to a clinician first

The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).

If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.